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Abstract
Background
Though complementary and alternative medicine (CAM) are frequently used by children
and adolescents with cancer, there is little information on how and why they use it. This
study examined prevalence and methods of CAM, the therapists who applied it, reasons for
and against using CAM and its perceived effectiveness. Parent-perceived communication
was also evaluated. Parents were asked if medical staff provided information on CAM to
patients, if parents reported use of CAM to physicians, and what attitude they thought physi-
cians had toward CAM.
Study Design
All childhood cancer patients treated at the University Children’s Hospital Bern between
2002–2011 were retrospectively surveyed about their use of CAM.
Results
Data was collected from 133 patients (response rate: 52%). Of those, 53% had used CAM
(mostly classical homeopathy) and 25% of patients received information about CAM from
medical staff. Those diagnosed more recently were more likely to be informed about CAM
options. The most frequent reason for choosing CAM was that parents thought it would
improve the patient’s general condition. The most frequent reason for not using CAM was
lack of information. Of those who used CAM, 87% perceived positive effects.
Conclusions
Since many pediatric oncology patients use CAM, patients’ needs should be addressed by
open communication between families, treating oncologists and CAM therapists, which will
allow parents to make informed and safe choices about using CAM.
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Introduction
Parents often choose complementary and alternative medicine (CAM) to supplement treat-
ment of children and adolescents with cancer [1–3]. In a recent systematic review, the preva-
lence of CAM use for patients with pediatric cancer ranged from 6%-91% [4], varying on a
country-by-country basis. Homeopathy and dietary supplements are most common in Ger-
many [5], while water therapy and Spirulina are popular in Malaysia, and herbal extracts in
Mexico [6,7]. Patients use a broad spectrum of CAMmethods, and some may interact with
conventional medicine, causing adverse effects [8–12]. In Switzerland CAM is very popular: a
2007 study showed 23% of the adult Swiss population had used CAM within the past year [13].
Zuzak et al. reported that 58% of patients who presented at a Swiss pediatric emergency depart-
ment had used CAM, but as yet, there is no data on how widespread CAM use is in pediatric
oncology [14]. Pediatric oncology patients often use CAM without telling the oncologists who
treat them [1,3,7,15,16].
Since 2010, a collaboration between the Division of Pediatric Hematology/Oncology at the
University Children’s Hospital and the Institute of Complementary Medicine (IKOM), both at
the University of Bern, exists. Parents of children with cancer who are hospitalized for the first
time receive detailed written information about the clinic including a sheet about CAM offers
of the IKOM. On request, families who want further information about CAM are referred by
the pediatric oncologist to the IKOM for counseling and/or complementary treatment. Those
patients are followed by the IKOMmedical staff once a week during hospital stays, and on
demand the IKOM staff provides outpatient care.
This study was designed to collect information on CAM use by childhood cancer patients,
focusing particularly on the following: (1) the overall proportion of patients who use CAM,
CAMmethods applied, and the therapists who provide CAM; (2) the reasons parents did or
did not choose CAM; (3) communication between parents and doctors about CAM, any
change over the past decade in the proportion of patients who were informed about CAM by
medical staff, and physicians’ attitudes regarding their patients’ use of CAM; and, (4) parent
and/or patient perceptions of the effectiveness of CAM.
Methods
Study Population
The study was carried out in collaboration with the Swiss Childhood Cancer Registry (SCCR,
www.childhoodcancerregistry.ch), which, since 1976, has included all children and adolescents
in Switzerland diagnosed with leukemia, lymphoma, central nervous system (CNS) tumors,
malignant solid tumors and Langerhans cell histiocytosis (LCH) before they were 21 [17]. This
study included all patients registered at the SCCR who were diagnosed between January 1st
2002 and December 31st 2011, were aged 0 to 18 years, and were treated at the Division of Pedi-
atric Hematology/Oncology at the University Children’s Hospital Bern, Switzerland. Exclusion
criteria were death within 2 months of diagnosis, and the parents’ refusal to participate in a
questionnaire survey.
The SCCR was granted ethical approval through the general cancer registry permission
(issued by the Swiss Federal Commission of Experts for Professional Secrecy in Medical
Research) and a non obstat statement was obtained from the ethics committee of the canton of
Bern. For the survey on CAM use, ethical approval was not necessary at the time of the study
conduction. Written informed consent was obtained by the participants.
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Questionnaire Survey
A German language questionnaire on CAM use was designed for the parents of children with
cancer. It was based on published international studies and specifications of CAM use in Swit-
zerland [1–3,15,16,18,19]. There were a total of 18 questions: six questions about socio-demo-
graphic background and conventional cancer treatment, followed by 12 questions about CAM
use.
The questionnaire was tested for comprehensibility by 12 people (six healthy adults, four
physicians and two adolescent patients). On May 29th 2012, the questionnaires were mailed to
families with a cover letter, detailed study information and an informed consent form. Patients
who did not return the informed consent and questionnaire within 6 weeks received a postal
reminder. Along with the reminder, families who lived in the French speaking part of Switzer-
land received a second questionnaire in French.
Definition and Assessment of CAM Use
There is no generally accepted definition of CAM [20], but the one most commonly used was
issued by the U. S. National Center for Complementary and Integrative Health (NCCIH).
NCCAM defines CAM as a group of diverse medical and health care systems, practices, and
products not generally considered part of conventional medicine [21]. CAM practices are
grouped into three categories: natural products; mind-body medicine; and, manipulative body-
based practices.
In our questionnaire, we assessed the way families used CAM before and after the cancer
diagnosis, and asked which therapies they had used. Respondents could select from 43 listed
CAM therapies and treatments, and could have reported additional methods. CAMmethods
were grouped into six categories for this analysis: medicaments and remedies (e.g., homeopa-
thy, traditional Chinese medicine, Ayurveda); regulatory therapies (e.g., acupuncture, shiatsu);
nutrition (e.g., dietary supplements, juice diet); mind-body therapies (e.g., yoga, music ther-
apy); manual therapies (e.g., massages, chiropractic); and, other therapies (i.e., bioresonance
therapy, electromagnetic therapy). We asked who provided these therapies (e.g., physician,
non-medical practitioner or therapist or parents), whether CAM was used in a complementary
fashion, or as an alternative to conventional treatment, and if CAM users would recommend
that therapy to other patients and families. CAM users and non-CAM users were asked why
they did or did not use CAM. CAM users were also asked if they had told the treating oncolo-
gist, their primary care physician, or pediatrician about the additional therapies they had used,
and, if so, what the doctor´s reaction had been. Families were also asked if medical staff had
informed them about CAM therapies when they discussed cancer treatment, and if they would
have wanted to receive this information from their treating physician. The survey also asked if
CAM users thought the therapies they tried were effective (positive or negative effect, or both)
and asked them to specify the effects they attributed to CAM therapy.
Assessment of Socio-demographic and Cancer-related Data
This study extracted baseline demographic data and prospectively collected medical informa-
tion on diagnosis and treatment of patients from the SCCR, including age, gender, cancer diag-
nosis, age at diagnosis, cancer treatment, relapse, and time since diagnosis. The International
Classification of Childhood Cancer, 3rd Edition (ICCC-3) was used to classify diagnoses [22].
Treatment was classified as surgical tumor resection (yes/no), chemotherapy (CTX; yes/no),
radiotherapy (RTX; none, body and limb irradiation, cranial and spinal irradiation), and bone
marrow or peripheral blood stem cell transplantation.
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Statistical Analysis
Results are presented as descriptive statistics, with percentages and 95% confidence intervals
(95% CI). Characteristics of participants included into the analysis and of non-participants
were compared with chi-square-tests (gender, deceased at time of study, diagnoses) and t-test
(age), accordingly. The Cochran-Armitage test for trend was used to assess if the proportion of
patients told about CAM by medical staff had increased over the last decade. Data were ana-
lyzed with the Statistical Package for Social Sciences (IBM SPSS, version 21.0, IBM Corp.,
Armonk, NY).
Results
Characteristics of the Study Population
Of 303 eligible patients, 46 were excluded due to the exclusion criteria or because their mail
was undeliverable (Fig 1). A total of 257 families were contacted. Of these, 141 (55%) returned
Fig 1. Inclusion process and eligibility of study participants. a) Diagnosed between January 1st 2002 and
December 31st 2011, aged 0 to 18 years at diagnosis, treated at the Division of Pediatric Hematology/
Oncology at the University Children’s Hospital Bern, Switzerland.
doi:10.1371/journal.pone.0145787.g001
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the questionnaire. Eight questionnaires (3%) were excluded leaving 133 questionnaires (52%)
in the final analyses. Children from participating families did not differ from children of non-
participants regarding sex, age, and diagnosis (all p-values> 0.14; S1 Table). The only differ-
ence was a higher proportion of deceased children (25% vs. 11%, p< 0.01) in non-participants.
Of the 133 participants included mean age at diagnosis was 6.6 years (SD = 4.9; Table 1); 63
(47%) were girls. By the time the survey was mailed, 15 patients (11%) had died. The most
common diagnoses were leukemia (31%), CNS neoplasms (24%) and lymphomas (16%). Most
children (93%) had finished conventional cancer treatment, which consisted of CTX (83%),
RTX (29%), and surgery (44%). Most parents had completed vocational training or upper sec-
ondary education (77% mothers; 62% fathers). Most families had a monthly family-income
between CHF 5.000 and 10.000 (64%). Mothers completed the majority of questionnaires
(90%).
Use of CAM
About half of the participating families (n = 70, 53%) reported that they used CAM before their
child was diagnosed with cancer. Of these families, 54 (77%) continued to use CAM after the
cancer diagnosis, and 17/63 families who had not previously used CAM (24%) began to use it.
Of participating patients, 53% (n = 71) reported they used CAM after the cancer diagnosis
(Table 2). Among CAM users, the most common methods applied after diagnosis were classi-
cal homeopathy (54%), dietary supplements (31%), prayer/faith (30%), and over-the-counter
homeopathy (27%).
About half of CAM users (n = 32, 45%) used one or two methods, and the other half
(n = 39, 55%) used more than two methods. Almost all CAM users (n = 63, 89%) reported that
their CAM use complemented conventional treatment. For palliative therapy, four respondents
(6%) used only CAM (no conventional treatment). One family reported that when their child
entered a palliative phase, they stopped using CAM as a complement and began using it as an
alternative treatment.
The therapists who treated patients with CAM were mostly non-medical practitioners
(47%), physicians (41%), and parents (41%; Table 3). In 56% (n = 40) of cases, no physician
was involved in CAM therapy.
Reasons for or against Choosing CAM
The most important reasons for using CAM were a wish to improve the patient’s general con-
dition (75%), to strengthen their immune system (66%), and to reduce adverse effects of con-
ventional treatment (60%; Table 3). The main reasons parents did not choose CAM were not
enough information about CAM (31%), the belief that CAM is ineffective (31%), and desire to
avoid putting the child under more stress (27%).
Information and Communication about CAM
Most parents (n = 53, 75%) reported that they told treating oncologists they were using CAM
to treat their children. Over half the participating families had not been told that CAM was
available (n = 79, 59%), 33 (25%) were informed; and 21 (16%) could not remember. About
half of the participants (n = 71, 53%) noted that they would have appreciated information
about possible treatment with CAM, while 47 (35%) would not have wanted this information,
and 15 (11%) did not answer the question. Over the studied years of diagnoses (2002–2011),
the proportion of families who learned about CAM from medical staff increased (ptrend =
0.034). Of families with children diagnosed 2002–2006 17% were informed about CAM by hos-
pital staff. In 2007–2011, this increased to 32% of families with children diagnosed. Most CAM
CAMUse in Pediatric Oncology Patients
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Table 1. Characteristics of the Participants included into the Analysis (N = 133).
Variables Number (percentage)
Clinical information 133 (100)
Age at diagnosis
0–4 years 60 (45)
5–9 years 29 (22)
10–13 years 28 (21)
14–18 years 16 (12)
Gender
Female 63 (47)
Male 70 (53)
Deceased at time of study 15 (11)
Diagnoses (ICCC-3 main group)
(1) Leukemia, myeloproliferative diseases and myelodysplastic syndrome 41 (31)
(2) Lymphoma and reticuloendothelial neoplasms 21 (16)
(3) CNS tumors and miscellaneous intracranial and intraspinal neoplasms 32 (24)
(4) Neuroblastoma and other peripheral nervous cell tumors 9 (7)
(8) Malignant bone tumors 7 (5)
(9) Soft tissue and other extraosseous sarcomas 8 (6)
Other diagnoses a) 15 (11)
Conventional treatment b)
CTX 110 (83)
Surgery 59 (44)
RTX 38 (29)
Blood stem cell transplantation 15 (11)
Treatment status
On treatment at time of study 7 (5)
Treatment ﬁnished at time of study 124 (93)
Missing answer 2 (2)
Sociodemographic information
Monthly family-income (n = 121)
< CHF 5.000 17 (14)
CHF 5.000–10.000 77 (64)
> CHF 10.000 27 (22)
Mothers’ education
Compulsory school 9 (7)
Vocational training/upper secondary education 103 (77)
University 18 (14)
Missing answer 3 (2)
Fathers’ education
Compulsory school 8 (6)
Vocational training/upper secondary education 83 (62)
University 37 (28)
Missing answer 5 (4)
Respondent b)
Mother 119 (90)
Father 34 (26)
Child 9 (7)
Others 1 (1)
ICCC-3, International Classiﬁcation of Childhood Cancer, 3rd Edition; CNS, central nervous system; CTX,
chemotherapy; RTX, radiotherapy.
a) Including ICCC-3 main groups: (6), (7), (10), (11) and (14);
b) Multiple answers possible.
doi:10.1371/journal.pone.0145787.t001
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Table 2. Usage of CAM in Childhood Cancer Patients.
CAM users after cancer
diagnosis (n = 71)
All patients (N = 133)
Overall use of CAM Number (%) 95% CIa) (%) 95% CIa)
CAM usage after the cancer diagnosis 71 - (53) 44–62
No CAM usage after the cancer diagnosis 62 - (47) 38–56
Number of CAM methods used 71 (100) (53)
1 method used 19 (27) 16–37 (15) 9–20
2 methods used 13 (18) 10–28 (10) 5–15
3–4 methods used 15 (21) 12–30 (11) 6–17
>4 methods used 24 (34) 23–45 (18) 12–25
CAM use
Complementary 63 (89) 86–98 (47) 40–57
Alternative 4 (6) 1–12 (3) 1–7
Both 1 (1) 0–5 (1) 0–2
Missing 3 (4) (2)
Drugs and remedies (at least one method)b): 59 (83) 74–91 (44) 36–53
Classical Homeopathy 38 (54) 41–65 (29) 21–37
Over the counter Homeopathy 19 (27) 17–37 (14) 9–21
Bach ﬂowers 16 (23) 14–32 (12) 8–17
Spagyric 16 (23) 13–32 (12) 7–17
Schüssler Salts 15 (21) 12–31 (11) 6–17
Anthroposophic medicine 8 (11) 4–20 (6) 2–11
Herbal medicaments 6 (9) 3–15 (5) 2–8
Mistletoe therapy 5 (7) 1–13 (4) 0–7
Aromatherapy 3 (4) 0–10 (2) 0–5
Traditional Chinese medicine 2 (3) 0–8 (2) 0–4
Ayurveda 1 (1) 0–5 (1) 0–2
Regulatory therapies (at least one method)b): 18 (25) 16–36 (14) 8–20
Kinesiology 12 (17) 9–27 (9) 5–14
Acupuncture 5 (7) 2–14 (4) 1–8
Meridian therapy 3 (4) 0–10 (2) 0–5
Shiatsu 1 (1) 0–5 (1) 0–2
Nutrition (at least one method)b): 27 (38) 27–49 (20) 14–27
Dietary supplements 22 (31) 20–42 (17) 11–23
Special dietary change 7 (10) 4–18 (5) 2–10
Fasting or juice cure 2 (3) 0–8 (2) 0–4
Macrobiotics 1 (1) 0–5 (1) 0–2
Mind-body therapies (at least one method)b): 29 (41) 30–53 (22) 15–29
Prayer/Faith 21 (30) 19–41 (16) 10–22
Music therapy 11 (16) 7–24 (8) 4–13
Art therapy 4 (6) 1–12 (3) 1–7
Meditation 3 (4) 0–10 (2) 0–5
Autogenic training 1 (1) 0–5 (1) 0–2
Breath therapy 1 (1) 0–5 (1) 0–2
Biofeedback 1 (1) 0–5 (1) 0–2
Manual therapies (at least one method)b): 23 (32) 22–43 (17) 11–24
Osteopathy 9 (13) 5–20 (7) 3–11
Massage 7 (10) 3–18 (5) 2–10
(Continued)
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Table 2. (Continued)
CAM users after cancer
diagnosis (n = 71)
All patients (N = 133)
Overall use of CAM Number (%) 95% CIa) (%) 95% CIa)
Reﬂexology 6 (9) 2–16 (5) 2–8
Cranio-sacral therapy 3 (4) 0–9 (2) 0–5
Lymphatic drainage 1 (1) 0–5 (1) 0–2
Chiropractic 1 (1) 0–5 (1) 0–2
Acupressure 1 (1) 0–5 (1) 0–2
Others (at least one method)b): 19 (27) 17–36 (14) 9–21
Bioresonance therapy 10 (14) 6–24 (8) 4–13
Electromagnetic therapy 2 (3) 0–8 (2) 0–4
Other methods 15 (21) 12–31 (11) 6–17
CAM, Complementary and alternative medicine; CI, conﬁdence intervals.
a)Bootstrapped CI for percentage;
b)Multiple answers possible.
doi:10.1371/journal.pone.0145787.t002
Table 3. Information on the Therapist applying CAM, and parent-reported Reasons for and against
CAMUse.
Applying therapist a) Number (percentage)
Non-medical practitioner b) 33 (47)
Physician 29 (41)
Parents 29 (41)
Pharmacist 10 (14)
Non-medical therapist c) 14 (20)
Missing 2 (3)
Reasons for CAM use (n = 71) a) Number (percentage)
To improve general condition 53 (75)
To strengthen the immune system 47 (66)
To reduce side effects of conventional treatment 42 (60)
To improve the chance of cure 35 (49)
For relaxation 34 (48)
Trying all possible therapies 15 (21)
Other reasons 3 (4)
Reasons for no CAM use (n = 62) a) Number (percentage)
Lacking information on CAM 19 (31)
Belief that CAM is ineffective 19 (31)
To avoid further stress 17 (27)
Fear of interactions with conventional treatment 10 (16)
Adequate efﬁcacy and/or good tolerance of conventional treatment 10 (16)
Oncologist discouraged from CAM 7 (11)
Fear of side effects of CAM 2 (3)
Family doctor discouraged CAM use 2 (3)
Other reasons 3 (5)
CAM, complementary and alternative medicine.
a) Respondents could indicate more than one answer.
b) Non-medical practitioners apply acupuncture, homeopathy or naturopathy.
c) Non-medical therapists apply different non-interventional therapies like e.g., kinesiology, massage.
doi:10.1371/journal.pone.0145787.t003
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users learned about CAM from friends (n = 32, 45%) and family (n = 22, 31%), other unspeci-
fied sources (n = 18, 25%), family doctors/pediatricians (n = 17, 24%), media (n = 16, 23%),
other parents (n = 12, 17%), oncologists (n = 8, 11%), or nonmedical practitioners (n = 8,
11%). Family doctors and pediatricians were more supportive of CAM use than were pediatric
oncologists (Table 4).
Perceived Effectiveness
Most CAM users thought the CAMmethods they used had positive effects (n = 62, 87%). A
belief that the patient’s general condition had improved was most common (n = 54, 76%;
Fig 2).
Table 4. Physicians informed by the Families about CAMUse and their Reactions (CAM users; n = 71).
Physicians informeda) Pediatric oncologists: number
(percentage)
Family doctors/ pediatricians: number
(percentage)
Other doctors: number
(percentage)
Yes 53 (75) 37 (52) 6 (8)
No 16 (23) 32 (45) 63 (89)
Answer missing 2 (3) 2 (3) 2 (3)
Physicians’ reactions b)
Agreed with CAM use 15 (28) 21 (57) 3 (50)
Took note of CAM use 26 (49) 14 (38) 3 (50)
Warned against CAM 9 (17) 1 (3) -
Reaction not
remembered
2 (4) - -
Answer missing 3 (6) 3 (8) -
CAM, complementary and alternative medicine.
a) Multiple physicians could be informed.
b) Percentages refer to the respective number of physicians informed.
doi:10.1371/journal.pone.0145787.t004
Fig 2. Perceived effects of CAM by the 71 users (100%; one answer missing). CAM, complementary and alternative medicine; CTX, chemotherapy;
RTX, radiotherapy. Respondents could indicate more than one positive effect.
doi:10.1371/journal.pone.0145787.g002
CAMUse in Pediatric Oncology Patients
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Almost all CAM users would recommend that other families try the methods they applied
(n = 64, 90%). The main reason parents would not recommend CAM (n = 3, 4%) is that they
believe that the choice to use CAM or not is an individual one, to be made by each patient/fam-
ily (missing n = 4, 6%).
Discussion
Over half (53%) of survey responders treated at this tertiary care pediatric oncology center
used CAM, most commonly in the form of classical homeopathy. CAM added to conventional
cancer treatments, not a substitute for them. A physician was involved in CAM therapy for less
than half (41%) of patients. Mainly patients were treated by non-medical practitioners or by
parents. The main reason parents gave for using CAM was to improve the patient’s general
health. Important reasons for not using CAM were lack of information (31%), or a belief that
CAM is ineffective (31%). Most parents (75%) told their pediatric oncologist that they were
using CAM. Over the past ten years, the proportion of patients told about CAM by medical
oncology staff increased. Family doctors and pediatricians were more supportive of CAM than
pediatric oncologists. The majority of CAM users (87%) thought that CAM therapy had
helped.
Comparison with other studies and interpretation of results
This pediatric cancer patients from our Swiss study used CAMmore often than pediatric can-
cer patients in other European countries [1,2,15]. But findings are in line with a recent survey
conducted at a Swiss pediatric emergency department, where 58% of patients had used or were
currently using CAM [14]. As in other studies from European countries, the most common
CAM therapies were homeopathy and over-the-counter medications [2,5,15]. Though a survey
from Germany found that anthroposophical medicine (including mistletoe therapy) was com-
monly used [5], this was not the case in Switzerland.
The systematic review by Bishop et al. found that most parents chose CAM to support con-
ventional treatment, cure or fight the child’s cancer, and provide symptomatic relief [4], and
the results from this study are similar. Most parents (75%) wanted to improve the child’s gen-
eral condition (75%), strengthen the immune system (66%), and improve their chances of cure
(49%). But this study also evaluated the reasons parents did not use CAM [2–4,6,7,15,16]. As
in studies by Längler et al. and Fernandez et al., this study found that a major reason why
parents did not choose CAM as an add-on therapy was lack of information [1,23]. Another rea-
son, not mentioned so far in the literature, is that many parents thought CAM was unnecessary
since the patient tolerated conventional treatment well and it was effective.
Like parents in Germany, most parents in Switzerland told treating physicians they were
using CAM [1]. A study fromMexico found that only 9% of CAM users informed their physi-
cians [7]. CAMmight be less accepted by both the general population and physicians in
Mexico. In Switzerland, parents reported that family doctors were usually supportive, but most
pediatric oncologists simply noted CAM usage, rather than taking a position for or against it. It
is possible that pediatric oncologists do not have in-depth knowledge about CAM therapies. A
U.S. study found that only 43% of pediatric oncologists asked their patients if they used CAM;
the main reason they did not ask was that they knew little about CAMmethods (93%) [24].
This study found that over half of pediatric oncologists would like to learn more about CAM
methods [24]. The majority (99%) believed that it is important to know about CAM in order to
prevent harmful drug interactions between CAM and conventional cancer treatment.
A Dutch study had similar results to this one: 88% of all respondents would have liked it if
their treating physician had given them information on CAM treatment; 64% of the parents
CAMUse in Pediatric Oncology Patients
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would have liked it if CAMmethods had been offered in the hospital [15]. A survey in Israel
showed that childhood cancer patients would have liked to receive CAM therapy at the same
hospital where they were conventionally treated [16].
In families with a child diagnosed more recently (2007–2011), a higher proportion of
parents were told about CAMmethods than in families where the child had been diagnosed
earlier (2002–2006). Perhaps pediatric oncologists are now more aware of their patients’ use of
CAM and understand there is a need for open communication on the topic. Oncologists may
be more aware because discussion of CAM has increased at the pediatric oncology unit, due to
staff members becoming more aware of different CAMmethods, or because CAM physicians
from the IKOM were regularly consulted in the department. Referred patients who decided to
add CAM therapies to conventional cancer treatments were visited by the IKOMmedical staff
once a week while they were hospitalized. This fostered direct communication between pediat-
ric oncology and IKOM staff.
From our findings that CAM was applied mainly by non-medical therapists and as self-
medication by the parents arises some questions about i) the ability of non-medical therapists
in the treatment of children with cancer; ii) how parents choose and prescribe CAM-medica-
ments and iii) a possible difference in the benefit of CAM used in combination with conven-
tional therapy prescribed and applied by CAM-physicians, non-medical therapists or self-
medication. To our knowledge there are no investigations about these topics.
Like a recent study from the Netherlands, where 49% of the patients thought CAM was very
effective, and 26% thought it somewhat effective, this study found that most parents believed
CAM was effective (87%) [15]. Most parents (90%) would recommend CAM to other families.
Methodological considerations
The response rate of 55% was acceptable. Only 8 questionnaires (3%) had to be excluded,
which suggests that most participants understood the questions. Socio-demographic and clini-
cal characteristics did not differ between participants included into the analysis and non-par-
ticipants, except for the survival rate, which was higher in participants. Therefore it is unclear,
if the data presented for parents of children who died are fully representative for this group.
Because of the survey’s retrospective design, memory bias might have influenced the outcome.
Since this study was carried out in a single pediatric cancer center, it might not represent all of
Switzerland. We cannot exclude sampling bias, possibly by a higher response rate of families
interested in CAM or by more educated individuals.
Conclusions
Further study is required to determine what patients, pediatric oncologists and other healthcare
professionals need to know about CAM use, and its risks and benefits in treating childhood
cancer. For patient safety and best care, pediatric oncologists and primary care physicians
should learn more about CAMmethods, and CAM providers should learn about conventional
cancer treatments. Physicians should ask their patients if they use any form of CAM and advise
users to cooperate with qualified CAM physicians. Coordination and cooperation between
pediatric oncologists and CAM physicians could improve patient care by opening communica-
tion, increasing mutual understanding, increasing patient satisfaction, compliance and, ulti-
mately, safety.
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S1 Table. Characteristics of Study Participants included into the Analysis and of Non-par-
ticipants. ICCC-3, International Classification of Childhood Cancer, 3rd Edition; CNS, central
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ing ICCC-3 main groups: (6), (7), (10), (11) and (14).
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